Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial

What Was Tested

The paper reports a study of Liraglutide, published as a randomized controlled trial.

Treatment options beyond metformin and insulin are needed.

Who Took Part

By PubMed's age tags, the people studied were children and teenagers.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.

As a double-blind Liraglutide study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Liraglutide group a baseline to be compared against.

The timeline in the abstract includes 5 weeks.

What Was Measured

Topics PubMed links to this paper include Age of Onset, Belgium, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptide 1, Glycated Hemoglobin and Hypoglycemic Agents.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Liraglutide over 5 weeks.

The abstract goes on to report its results in about 9 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Diabetes technology & therapeutics), a journal based in United States.

More context: the Liraglutide compound page, all human trials.